Table 1.
Demographic summary ApoE load, olfactory testing, cognitive evaluation, amyloid Aβ and MoCA index in NCI, MCI and AD patients
| Age | Gender | ApoE load | Olfactory Connecticut test * (threshold/identification/index score) | Amyloid Aβ expression | MoCA index | MRI | Cognitive evaluation |
|---|---|---|---|---|---|---|---|
| 67 | M | 3/3 | Bilateral anosmic (0/0/0) | − | 28 | Vasogenic leukoencephalopathy | NCI |
| 46 | M | 3/3 | Bilateral anosmic (0/0/0) | − | 27 | Demyelination in the frontal gyrus | NCI |
| 76 | M | 3/3 | Bilateral anosmic (0/0/0) | − | 26 | Vasogenic leukoencephalopathy | NCI |
| 56 | F | 3/4 | Hyperosmic normal (7/7/7)) | − | 28 | Lacunar infarcts | NCI |
| 62 | F | 3/4 | Bilateral anosmic (0/0/0) | − | 27 | Olfactory bulb | NCI |
| 57 | M | 3/3 | Slight hyposmic right (5.5/6/5.5) | + | 25 | Vasogenic leukoencephalopathy | MCI |
| 41 | M | 3/4 | Normosmic (7/7/7) | + | 25 | normal | MCI |
| 63 | M | 4/4 | Bilateral anosmic (0/0/0) | + | 24 | Vasogenic leukoencephalopathy | MCI |
| 77 | M | 3/4 | Bilateral anosmic (0/0/0) | +++ | 23 | Marked changes involutive hippocampal shrinkage | ADII |
| 74 | F | 4/4 | Bilateral anosmic (0/0/0) | ++ | 19 | Bilateral hippocampal atrophy | ADII |
AD = Alzheimer's disease; ApoE = apolipoprotein E; * = arbitrary intensity of fluorescence; MCI = mild cognitive impairment; MoCA = Montreal Cognitive Assessment; MRI = magnetic resonance imaging; NCI = noncognitive impaired